Cytosorbents
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 186
- Market Cap
- $56.6M
- Introduction
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
CytOSorb TreatMent Of Critically Ill PatientS Registry
- Conditions
- Cardiogenic ShockPancreatitisExtracorporeal Life SupportPostoperative EndocarditisPostoperative Vasoplegic SyndromeHemophagocytic LymphohistiocytosesTraumaRhabdomyolysisAcute on Chronic Liver FailureLiver Transplant; Complications
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- CytoSorbents, Inc
- Target Recruit Count
- 3000
- Registration Number
- NCT05146336
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
🇦🇹Medizinische Universität Wien, Wien, Austria
🇩🇪Universitätsklinikum Aachen, Aachen, Germany
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
- Conditions
- Blood Loss, PostoperativeHemorrhage PostoperativeHemorrhage, SurgicalBlood Loss, Surgical
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- CytoSorbents, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT05093504
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Safe and Timely Antithrombotic Removal (STAR) Registry
- Conditions
- Blood Loss, SurgicalBlood Loss, PostoperativeHemorrhage, SurgicalHemorrhage Postoperative
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- CytoSorbents, Inc
- Target Recruit Count
- 1000
- Registration Number
- NCT05077124
- Locations
- 🇦🇹
Universitätsklinikum Graz, Graz, Austria
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
- Conditions
- Blood Loss, PostoperativeHemorrhage PostoperativeBlood Loss, SurgicalHemorrhage, Surgical
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- CytoSorbents, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT04976530
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
Registry of CytoSorb Therapy in COVID-19 ICU Patients
- Conditions
- COVID-19
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- CytoSorbents, Inc
- Target Recruit Count
- 138
- Registration Number
- NCT04391920
- Locations
- 🇺🇸
Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Franciscan Health Indianapolis, Indianapolis, Indiana, United States
- Prev
- 1
- 2
- Next
News
FDA Denies CytoSorbents' De Novo Request for DrugSorb-ATR Blood Purification Device
The FDA has issued a denial letter for CytoSorbents' DrugSorb-ATR device, designed to reduce bleeding in CABG surgery patients who recently took ticagrelor, citing unresolved deficiencies.
CytoSorbents Seeks Approval for DrugSorb-ATR in Canada to Reduce Bleeding in Heart Surgery
CytoSorbents has submitted a Medical Device License application to Health Canada for DrugSorb-ATR, targeting reduced bleeding during CABG surgery in patients on ticagrelor.